Rapids

RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas

Retrieved on: 
Thursday, November 9, 2023
Apps, Applications, Technology, Surgery, FDA, Health Technology, Cardiology, Software, General Health, Health, Artificial Intelligence, Stroke, Intelligence, ICH, Rapids, PACS, Mortality, Trauma, Bleeding, Artificial intelligence, Traumatic brain injury, Epidural hematoma, AI, Patient, SDH, Medical device, Nursing

RapidAI , the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, today announced it has received FDA clearance for Rapid SDH, its AI-powered module for the detection and notification of suspected hemispheric acute and chronic subdural hematoma.

Key Points: 
  • RapidAI , the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, today announced it has received FDA clearance for Rapid SDH, its AI-powered module for the detection and notification of suspected hemispheric acute and chronic subdural hematoma.
  • Together with Rapid ICH and Rapid Hyperdensity , the three modules comprise RapidAI’s unique and industry-best hemorrhagic and trauma care AI solution, designed to help teams on the front lines of patient assessment streamline decision making and expedite patient care.
  • The need for the RapidAI solution is urgent, with SDH cases in US patients expected to increase by nearly 80% before 2040 and current estimated mortality rates at 40-60% – underscored by neurosurgical workforce shortages across the country.
  • Rapid SDH leverages AI and the intelligence gained from analyzing hundreds of patient scans to help neurocritical care teams identify suspected hemispheric subdural hemorrhage faster and with a higher degree of accuracy than traditional methods.

Nuclear Decommissioning Services Market size in Europe to grow by USD 1.84 billion from 2023 to 2028; Growing government inclination toward renewable energy to drive the growth- Technavio

Retrieved on: 
Tuesday, November 7, 2023
FITS, Element, BWR, Rapids, PWR, Void coefficient, Government, Pressure, Electricite du Laos F.C., Wind, International, AECOM, Westinghouse Electric Corporation, Sample, Nature, Jacobs Solutions, Growth, Plant, Qualcomm, Radiation, USD, Radioactive waste, YOY, EU, Uranium mining, Thermoplastic, Beauty salon

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The nuclear decommissioning services market in Europe is expected to grow by USD 1.84 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The nuclear decommissioning services market in Europe is expected to grow by USD 1.84 billion from 2023 to 2028.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.
  • View PDF Sample
    The growing government inclination toward renewable energy is a key factor driving market growth.
  • The Rapid Thermal Processing Equipment Market size is estimated to grow at a CAGR of 6.39% between 2022 and 2027.

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

Retrieved on: 
Friday, November 3, 2023
FDA, Society for Immunotherapy of Cancer, Trial of the century, IND, Rapids, Prostate cancer, Antigen, News, Cytokine, HAL, RMIT Platform Technologies Research Institute, Immune system, Nature, Cell, HIV disease progression rates, Poster, SITC, Immunotherapy, B cell, NK, Cancer, Breast cancer, LINK, GM-CSF, Therapy, BCT, Patient, Breast, TSX, HLA, CD86, Vaccine, Medical imaging, Pharmaceutical industry

“We expect our novel immunotherapies to boost the immune system in cancer patients leading to tumor destruction.

Key Points: 
  • “We expect our novel immunotherapies to boost the immune system in cancer patients leading to tumor destruction.
  • Platform Technology: These findings support further development of BriaCell’s platform of next-generation cancer immunotherapies for multiple cancer types, focusing initially on breast, and prostate cancers.
  • In summary, BriaCell’s novel next generation personalized immunotherapy delivers broad immune responses against various solid tumor models via multiple immune activating mechanisms.
  • This opens the path to the clinic for Bria-OTS™, the first generation of BriaCell’s personalized off-the-shelf cellular immunotherapy for breast cancer.

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Retrieved on: 
Tuesday, September 26, 2023
PROMIS, BMC, Pros, Pediatric emergency medicine, Pediatrics, PD, Therapy, Hypophosphatemia, BSAP, Fatigue, Medicine, Phase II, New Çeltek events, Biomarker, BMD, Appetite, Hives, Pyrophosphate, Parallel Walk Test, Rapids, Alkaline phosphatase, Pain, Bruise, ET, Clinical trial, Bleeding, ADAS, Patient, Physician, PXE, Swelling, Itch, Erythema, Division, Adolescence, Osteomalacia, Infant, DEXA, Rickets, GIC, ADA, Diabetes, Titanium metallic discoloration, Safety, Dietary supplement, Pharmaceutical industry, Nursing, Medical imaging, Phosphorus, Birth control, Risk management, Vaccine, Endocrinology, News

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Key Points: 
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.
  • Exploratory biomarker data were collected throughout the study to provide evidence of the potential for disease modification with ongoing treatment with INZ-701.
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • PK properties were consistent with those observed in the Phase 1/2 clinical trial in adults with ENPP1 Deficiency.

NICE Rapid Expands Service: Cutting-Edge Silicone Moulding Services in Precision Engineering

Retrieved on: 
Tuesday, September 26, 2023
Rapids, Certification, Communication, Engineering, ISO, Molding (process), Electronics, Injection moulding, Pharmaceutical industry

NICE Rapid is a leading provider of precision manufacturing, injection moulding, and rapid tooling solutions.

Key Points: 
  • New York, New York--(Newsfile Corp. - September 26, 2023) - NICE Rapid , a distinguished leader in the realm of precision engineering and rapid tooling solutions, proudly announces the expansion of its service portfolio with the introduction of state-of-the-art silicone moulding services.
  • With a steadfast commitment to excellence, NICE Rapid is poised to revolutionize the industry with its versatile silicone moulding offerings, including Compression Moulding and Liquid Silicone Rubber Moulding.
  • NICE Rapid's foray into this domain signifies a significant milestone in the company's mission to provide comprehensive, cost-effective, and reliable solutions for compression moulding , silicone moulding, and rapid tooling.
  • NICE Rapid's silicone moulding services encompass a range of capabilities, each designed to meet the unique needs and specifications of diverse industries.

NFI powers Austin’s CapMetro fleet electrification with 26 New Flyer zero-emission Xcelsior CHARGE NG™ buses

Retrieved on: 
Monday, September 18, 2023
New Flyer Xcelsior, Partnership, ST, EV, North American Bus Industries, Transport, Carbon, Rapids, EVS, OTC, TSX, City, VIC, Google LLC v. Oracle America, Inc., Capital, NFI, Rail transport, Central Texas, New Flyer

Originally announced in November 2021, the contract includes up to 126 40-foot and up to 15 60-foot battery-electric buses.

Key Points: 
  • Originally announced in November 2021, the contract includes up to 126 40-foot and up to 15 60-foot battery-electric buses.
  • NFI added a firm order for the 26 40-foot electric vehicles (EVs) to its backlog in the second quarter of 2023.
  • CapMetro is Austin Texas’ public transportation provider, with over 20 million annual boardings through bus, paratransit, and commuter rail services.
  • “Our partnership with CapMetro spans over 25 years, and, during this time, New Flyer has delivered more than 300 buses.

Clarivate Launches Enhanced Search Powered by Generative Artificial Intelligence

Retrieved on: 
Wednesday, August 9, 2023
Knowledge, Hallucination, Clarivate, UI, CLVT, Health care, Intelligence, Research, Success rate, Rapids, Organization, Google Knowledge Graph, Patient, Physician, Machine learning, Algorithm, Drug discovery, UX, Artificial intelligence, AI, Health, NYSE, Data science, Online shopping, Medical device

LONDON, Aug. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched its new enhanced search platform leveraging generative artificial intelligence (GenAI). GenAI has the potential to yield efficiencies across the entire Life Sciences & Healthcare value chain. The new Clarivate offering enables drug discovery, preclinical, clinical, regulatory affairs and portfolio strategy teams to interact with multiple complex datasets using natural language to obtain immediate and in-depth insights.

Key Points: 
  • LONDON, Aug. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched its new enhanced search platform leveraging generative artificial intelligence (GenAI).
  • The new Clarivate enhanced search platform addresses these obstacles by pairing billions of proprietary data points and over 100 years of deep industry and domain expertise with GenAI capabilities.
  • Commercialization is anticipated later this year, with plans to extend the knowledge base by integrating additional datasets from solutions, including: Cortellis Clinical Trials Intelligence ™, Cortellis Deals Intelligence ™, OFF-X ™ Safety Intelligence, Cortellis Drug Discovery Intelligence ™, Cortellis Regulatory Intelligence ™ and others.
  • To learn more about the Clarivate enhanced search platform, contact: [email protected] .

Clarivate Launches Enhanced Search Powered by Generative Artificial Intelligence

Retrieved on: 
Wednesday, August 9, 2023
Knowledge, Hallucination, Clarivate, UI, CLVT, Health care, Intelligence, Research, Success rate, Rapids, Organization, Google Knowledge Graph, Patient, Physician, Machine learning, Algorithm, Drug discovery, UX, Artificial intelligence, AI, Health, NYSE, Data science, Online shopping, Medical device

LONDON, Aug. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched its new enhanced search platform leveraging generative artificial intelligence (GenAI). GenAI has the potential to yield efficiencies across the entire Life Sciences & Healthcare value chain. The new Clarivate offering enables drug discovery, preclinical, clinical, regulatory affairs and portfolio strategy teams to interact with multiple complex datasets using natural language to obtain immediate and in-depth insights.

Key Points: 
  • LONDON, Aug. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched its new enhanced search platform leveraging generative artificial intelligence (GenAI).
  • The new Clarivate enhanced search platform addresses these obstacles by pairing billions of proprietary data points and over 100 years of deep industry and domain expertise with GenAI capabilities.
  • Commercialization is anticipated later this year, with plans to extend the knowledge base by integrating additional datasets from solutions, including: Cortellis Clinical Trials Intelligence ™, Cortellis Deals Intelligence ™, OFF-X ™ Safety Intelligence, Cortellis Drug Discovery Intelligence ™, Cortellis Regulatory Intelligence ™ and others.
  • To learn more about the Clarivate enhanced search platform, contact: [email protected] .

Rapid Applications Group raises significant growth equity financing to help heavy equipment construction subcontractors run their operations

Retrieved on: 
Wednesday, August 2, 2023
Software as a service, GPS, Construction, ERP, App Store (iOS/iPadOS), Rapids, Collection, Growth, ROI, Mobile phone

BOSTON, Aug. 2, 2023 /PRNewswire/ -- Rapid Applications Group (Rapid Apps), the leading ERP software solution for heavy equipment construction subcontractors, announced its significant growth equity financing led by Boston-based growth equity firm Wavecrest Growth Partners and MassMutual Ventures.

Key Points: 
  • BOSTON, Aug. 2, 2023 /PRNewswire/ -- Rapid Applications Group (Rapid Apps), the leading ERP software solution for heavy equipment construction subcontractors, announced its significant growth equity financing led by Boston-based growth equity firm Wavecrest Growth Partners and MassMutual Ventures.
  • Many of the largest heavy equipment subcontractors in the concrete, hydrovac, and crane space, including Brundage-Bone, Concrete Pump Partners, and Kinetic Industry, trust Rapid Apps every day to manage their operations and provide insight into performance and productivity.
  • We are excited to partner with Rapid Apps to help them to become the leading player in the heavy equipment space and to help them further fuel their growth."
  • "Rapid Apps offers heavy equipment subcontractors with the first platform combining SaaS and mobile applications to connect in-office and in-field operations," noted Eric Emmons, Managing Partner at MassMutual Ventures.

Medcura Inc. Appoints Jacob Rodman to Board of Directors, Preparing for LifeGel™ Flowable Hemostat Launch and Expanding Market Reach

Retrieved on: 
Tuesday, July 18, 2023
Powder, Walmart, American Education Society, CVS, Rapids, Paralysis, Hospital, Hemostasis, Swelling, Neurosurgery, FDA, Trauma, Walgreens, Amazon, Nerve

RIVERDALE, Md., July 18, 2023 /PRNewswire/ -- Medcura Inc., proudly announces the appointment of Jacob Rodman to its Board of Directors.

Key Points: 
  • RIVERDALE, Md., July 18, 2023 /PRNewswire/ -- Medcura Inc., proudly announces the appointment of Jacob Rodman to its Board of Directors.
  • Jacob is the CEO of Raleigh Neurosurgical Clinic, Inc., and the president-elect of Nerves (Neurosurgery Executives Resource Value & Education Society).
  • "We are delighted to welcome Jacob Rodman to our Board of Directors.
  • Jacob Rodman expressed his regard for joining Medcura's Board of Directors, stating, "It is a privilege to serve on Medcura's Board of Directors.